Whole Genome Sequencing and the Genetics of Extramedullary Disease in Multiple Myeloma

Overview

Journal Blood Cancer J

Date 2025 Jan 11

PMID 39799110

Authors

Nicholas Bingham

Jaynish Shah

Daniel Wong

Sueh-Li Lim

Krystal Bergin

Anna Kalff

Antonia Reale

Tiffany Khong

Sridurga Mithraprabhu

Andrew Spencer

Affiliations

Soon will be listed here.

References

Vo J, Wu Y, Mishler J, Hall S, Mannan R, Wang L . The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma. Nat Commun. 2022; 13(1):3750. PMC: 9243087. DOI: 10.1038/s41467-022-31430-0. View

Gagelmann N, Eikema D, Iacobelli S, Koster L, Nahi H, Stoppa A . Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT. Haematologica. 2018; 103(5):890-897. PMC: 5927971. DOI: 10.3324/haematol.2017.178434. View

Walker B, Mavrommatis K, Wardell C, Ashby T, Bauer M, Davies F . Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018; 132(6):587-597. PMC: 6097138. DOI: 10.1182/blood-2018-03-840132. View

Bhutani M, Foureau D, Atrash S, Voorhees P, Usmani S . Extramedullary multiple myeloma. Leukemia. 2019; 34(1):1-20. DOI: 10.1038/s41375-019-0660-0. View

Landau H, Yellapantula V, Diamond B, Rustad E, Maclachlan K, Gundem G . Accelerated single cell seeding in relapsed multiple myeloma. Nat Commun. 2020; 11(1):3617. PMC: 7368016. DOI: 10.1038/s41467-020-17459-z. View

Maura F, Bolli N, Angelopoulos N, Dawson K, Leongamornlert D, Martincorena I . Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat Commun. 2019; 10(1):3835. PMC: 6707220. DOI: 10.1038/s41467-019-11680-1. View

Walker B, Wardell C, Murison A, Boyle E, Begum D, Dahir N . APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun. 2015; 6:6997. PMC: 4568299. DOI: 10.1038/ncomms7997. View

de Haart S, Willems S, Mutis T, Koudijs M, van Blokland M, Lokhorst H . Comparison of intramedullary myeloma and corresponding extramedullary soft tissue plasmacytomas using genetic mutational panel analyses. Blood Cancer J. 2016; 6:e426. PMC: 4916304. DOI: 10.1038/bcj.2016.35. View

Chan T, Yarchoan M, Jaffee E, Swanton C, Quezada S, Stenzinger A . Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2018; 30(1):44-56. PMC: 6336005. DOI: 10.1093/annonc/mdy495. View

10.

Ansari-Pour N, Samur M, Flynt E, Gooding S, Towfic F, Stong N . Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma. Blood. 2022; 141(6):620-633. PMC: 10163277. DOI: 10.1182/blood.2022017010. View

11.

Martinez-Jimenez F, Muinos F, Sentis I, Deu-Pons J, Reyes-Salazar I, Arnedo-Pac C . A compendium of mutational cancer driver genes. Nat Rev Cancer. 2020; 20(10):555-572. DOI: 10.1038/s41568-020-0290-x. View

12.

Rustad E, Yellapantula V, Glodzik D, Maclachlan K, Diamond B, Boyle E . Revealing the impact of structural variants in multiple myeloma. Blood Cancer Discov. 2021; 1(3):258-273. PMC: 7774871. DOI: 10.1158/2643-3230.BCD-20-0132. View

13.

Oben B, Froyen G, Maclachlan K, Leongamornlert D, Abascal F, Zheng-Lin B . Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Nat Commun. 2021; 12(1):1861. PMC: 7994386. DOI: 10.1038/s41467-021-22140-0. View

14.

Ashby C, Boyle E, Bauer M, Mikulasova A, Wardell C, Williams L . Structural variants shape the genomic landscape and clinical outcome of multiple myeloma. Blood Cancer J. 2022; 12(5):85. PMC: 9151656. DOI: 10.1038/s41408-022-00673-x. View